Benzinga··PrnewswireKazia Therapeutics Bolsters Oncology Pipeline with First-in-Class SETDB1 Inhibitor
Kazia in-licenses SETDB1 epigenetic platform from QIMR Berghofer to develop immunotherapy-resistant cancer treatment.
KZIAdrug developmentoncology